News & Updates
Excerpt from the Article: Charlottetown, PE – The Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced today Financial Awards of $5,000 for 32 post-secondary students across Atlantic Canada to support their academic studies in life sciences. This Financial Award program will support life sciences students enrolled in co-operative education from Acadia University, Université…
Read MoreExcerpt from the Press Release: United Kingdom (Precision Vaccinations) A commonly used anti-inflammatory treatment has been added to the Randomised Evaluation of COVid-19 thERapY (RECOVERY) study, the world’s largest clinical trial of treatments for patients hospitalized with COVID-19. Professor Peter Horby at the University of Oxford and co-Chief Investigator of the RECOVERY trial, said in…
Read MoreExcerpt from the Article: Pfizer Inc. and BioNTech SE requested emergency authorization of their Covid vaccine on Friday, and it could take at least three weeks for a U.S. Food and Drug Administration decision as trial data is probed by agency staff and outside advisers. Shown to be 95 percent effective and without any major…
Read MoreExcerpt from the Article: It goes without saying that COVID-19 has had a tremendous impact on our global society and economy. In fact, as lockdown was initiated across Europe at the start of March, we quickly saw the impact of this pandemic on clinical research activities across the various regions. Within the life sciences industry,…
Read MoreExcerpt from the article: Fluvoxamine, an antidepressant used to treat obsessive-compulsive disorder, may help prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19), results of an early clinical trial suggest. The double-blind, placebo-controlled, randomized study, published in JAMA, included 152 outpatients with COVID-19 in the St. Louis area between April 10 and August…
Read MoreExcerpt from the Press Release: TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX: PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that…
Read MoreExcerpt from the Press Release: Celltrion Group has completed enrolment of 327 patients with mild-to-moderate SARS-CoV-2 infection symptoms to evaluate anti-Covid-19 monoclonal antibody treatment candidate CT-P59 in the global Phase II clinical trial. Celltrion Group has completed enrolment of 327 patients with mild-to-moderate SARS-CoV-2 infection symptoms to evaluate anti-Covid-19 monoclonal antibody treatment candidate CT-P59 in…
Read MoreMarch 24, 2021 @ 11:00 am – 3:00 pm EDT The National Academies’ Forum on Drug Discovery, Development, and Translation will host a virtual public workshop on Mar 24, 2021 as part of a web series forum of events to discuss critical policy for advancement of biopharmaceutical innovation nationally and globally. This virtual public workshop…
Read MoreExcerpt from the Press Release: BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the presentation of new clinical data from three ongoing trials of Ad-RTS-hIL-12 plus veledimex (Controlled IL-12) for the treatment of recurrent glioblastoma (rGBM) and diffuse intrinsic pontine glioma (DIPG) at the 2020 Society…
Read MoreExcerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., today pre-published in vitro and in vivo data demonstrating its lead antibody candidate, ADG2, shows similar or higher potency against SARS-CoV-2 compared to monoclonal antibodies (mAbs) in clinical development, while also uniquely offering broad neutralization against a range of sarbecoviruses that pose a threat to…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?